Search

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-0.05% downside

Nieuwssentiment

By Acuity

18%

82%

39 / 340 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 jul 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 jul 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 jul 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 jul 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

31 jul 2026, 23:36 UTC

News

DoorDash Inc shares are lower in after-market trading amid concerns over order demand and rising fuel prices ahead of its upcoming Q2 earnings report.

31 jul 2026, 23:36 UTC

News

Warner Bros Discovery shares are lower in after-market trading amid concerns over job losses tied to Paramount's $81 billion acquisition and its extended offer deadlines.

31 jul 2026, 23:36 UTC

News

Bloom Energy Corp shares are lower in after-market trading amid a class action lawsuit alleging securities fraud related to its reliance on Chinese scandium.

31 jul 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

31 jul 2026, 23:31 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion, yet shares are trading lower in after-market hours following earlier volatility.

31 jul 2026, 23:26 UTC

News

Norwegian Cruise Line shares are lower in after-market hours following Citigroup's price target cut to $22 amid ongoing valuation concerns.

31 jul 2026, 23:26 UTC

News

NOW Inc shares are higher after market hours, reflecting positive sentiment in the trading companies sector and ongoing demand for energy products.

31 jul 2026, 23:26 UTC

News

Pomerantz LLP has filed a class action lawsuit against Verra Mobility Corp for securities fraud, contributing to lower after-market trading for the company.

31 jul 2026, 23:26 UTC

News

Roblox Corp's stock is lower in after-market hours following UBS's price target cut to $45 and a class action lawsuit announcement by Pomerantz LLP.

31 jul 2026, 23:16 UTC

News

KBR Inc. reported second-quarter revenue of $1.98 billion and reaffirmed full-year guidance, but shares are trading lower in after-market hours.

31 jul 2026, 23:16 UTC

News

Tractor Supply Co reported second-quarter revenue of $4.54 billion, missing expectations. Shares are trading lower in after-market hours following the earnings release.

31 jul 2026, 23:16 UTC

News

PBF Energy shares are lower in after-market hours following Citigroup's Neutral rating and price target increase to $74. The stock remains above its 20-day moving average.

31 jul 2026, 23:16 UTC

News

Huntington Ingalls Industries shares rise in after-market trading following strong Q2 results, with sales of $3.42 billion and a non-GAAP profit of $5.27 per share.

31 jul 2026, 23:16 UTC

News

Shares of GE Healthcare Technologies are lower in after-market trading following UBS's Neutral rating and a price target increase to $73.

31 jul 2026, 23:16 UTC

News

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

31 jul 2026, 23:16 UTC

News

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

31 jul 2026, 23:11 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blades, with shares trading higher in after-market hours.

31 jul 2026, 23:06 UTC

News

Hawaiian Electric Industries has signed a 30-year power purchase agreement, with shares trading higher in after-market hours.

31 jul 2026, 23:06 UTC

News

General Electric Co shares are lower in after-market trading, despite recent analyst upgrades and reaffirmed buy ratings for GE Aerospace.

31 jul 2026, 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

31 jul 2026, 23:06 UTC

News

Permian Resources Corp shares are trading higher in after-market hours following recognition as a top investment choice by Yahoo Finance, citing strong financial performance.

31 jul 2026, 23:06 UTC

Social Media
News

NVIDIA shares are lower in after-market trading despite strong fiscal first-quarter results, with revenues of $81.6 billion and record data center sales.

31 jul 2026, 23:06 UTC

News

Coinbase Global reported a record share of global crypto trading volume but also a significant net loss. Shares are roughly flat in after-market trading.

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD  -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

0

Buy

5

Hold

0

Sell

Sentiment

By Acuity

39 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

$

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat